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INTRODUCTION 
Gastric cancer(GC) is a major health burdenworldwide, ranking 4
th
 
among the malignant tumours and2
nd
 most common cause for cancer-related 
death. Patients with gastric cancer are usually diagnosed at an advanced stage of 
disease when curative treatment is not feasible and palliation is the only 
treatment option available.Clinical trials on chemotherapeutic drugs had shown 
only a moderate benefit in such advanced stage of cancer. Clinical trials also 
shown that even treatment with same drug, tumour cells show varying treatment 
response due to different degree of disease aggressiveness.Thus,some patients 
have dramatic response while some have poor responseto treatment. 
Subsequently, extensive research on tumour biology found that different 
subgroups of patients with unique clinical behaviour,biological aberrations and 
molecular vulnerabilities responded well to specific targeted chemotherapeutic 
agents. 
One such subgroup,tumor cells with overexpression of HER2protein were 
found to respond to targeted molecular therapy against HER2. Monoclonal 
antibody against HER2 receptor protein which modifies the signaling cascades 
involved in cell differentiation, proliferation and survival have shown better 
survival benefit in this subgroup of patients.One such anti HER2 agent is 
Traztuzumab and this agent had shown significant survival benefit in patients 
with HER2positive breast cancer. This agent isalso being tried in the subgroup 
of gastriccancer patients and shown survival benefits. 
Chua et al in a systemic review of 49 studies involving 11,337 patients 
reported HER2overexpression  inup to 53%,  with  a median of 18% in patients 
with gastric cancer. This overexpression was found to be associated with poorer 
survival. 
Lancet 2010; 376: 687–97 published that  chemotherapy incombination 
withTrastuzumab can be considered as a new standard option for patients with 
HER2-positive advanced gastric or gastro-oesophageal junction cancer and 
appropriate patient selection by HER2 IHC testing will now be part of routine 
pathology. 
Hence, we attempt to study the incidence,clinical, pathological 
characteristics of HER2 positivity in gastric malignancy in our population and 
to interpretits role in gastric malignancy. 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Gastric cancer(GC) is a major health  burden worldwide,ranking 4
th
 
among the malignant tumors and 2
nd
  most common cause for cancer-related 
death(10%).GC accounts for 8% of all newly-diagnosed cancer. There is wide 
variation in incidence of GC worldwide with higher incidence rates reported in 
East Asia(40 -60 per 100,000) and lower rates in Africa  and north America (0.3 
-3 per 100,000).In recent decades,it has been observed that there is gradual 
decrease in incidence in many population.However,not all types of gastric 
cancer are declining; tumor of cardia and esophagogastric junction are in 
increasing trend.Recently,an unexplained increase in younger individuals (<40 
yrs) has been reported. 
GLOBOCAN 2008 is the latest available source that gives figures of GC 
worldwise. About 73% of gastric cancer cases occur in Asia and almost half 
(47%) of world’s total occurs in china.The incidence rate varies worldwide 
being 60 per 100,000 in japan and korea to less than 6 per 100,000 in north 
America. High rates may also be due to good surveillance and detection of very 
small lesions.Based on this registry the age standardized  incidence rate in india 
are 11.9  and 5.8 per 100,000 among males and females respectively.Male to 
female ratio in incidence rates   is 2: 1 world wide consistently. 
The reason for regionalvariation of  incidenceof gastric cancer is 
multifactorial and wouldnot be attributed to a single factor like ethnicity. 
Environmental and dietary factors are found to have a strong influence on the 
varied geographical distribution. This strong influence is best demonstrated by 
epidemiological studies,in that, immigrants from high prevalence areas to low 
prevalence areas were observed to have reduced risk for gastric cancer. 
In India, based on the data from the National Cancer Registries, gastric 
cancer is a leading problem in North-eastern and Southern states of Indian. A 
nationally representative survey done recently revealed that second most 
common fatal cancer with mortality of 12.6% among 556,400 deaths in 2010.
1
 
North-eastern registries (Mizoram registry) mentioned   the highest rate 
of gastric cancer in India being 50.6 per 100,000 than the rest of the country. 
Overallthe gastric cancer incidence in India is less in comparison to other 
regions of the world. The age-adjusted rate (AAR) of gastric cancer among 
urban registries in India is (3.0–13.2) compared to the worldwide AAR (4.1–
95.5).
3
 The age-adjusted incidence rate of stomach cancer in males varies 
widely among registries, highest being 11.1 per 100,000 in Chennai compared 
to 1.6 per 100,000 in Bhopal.
5
 Similar to trends of stomach cancer globally, 
Indian registries have also observed statistically significant decreasing trend 
over the last 20-year.The difference in age of presentation(a decade earlier in 
south India) can be  attributed to the regional difference in incidence and 
presentation.
6
Among the  predisposing factors studied, varied dietary pattern 
along with  alcohol and tobacco were  considered  potential risk factors .A study 
from  Chennai  found  that one of the independent risk factors for gastric cancer 
were alcohol consumption and  use of pickled food.
4
 On the other hand, use of 
pulses was found to be offering protection.  
Distal gastric cancers were detected more commonly in individuals from lower 
socio-economic groups and developing countries like India. In patients with 
distal tumors,Helicobacterpylori (H. pylori) infection and varied dietary pattern 
were the mostcommon risk factors.Gastro esophageal reflux disease and obesity 
are said to be major risk factors for the development of proximal cancer which 
predominates in developed countries and higher socioeconomic groups. But, 
studies from areas of high incidence of H. pylori infection like Asia and Africa 
had shown there is no linear correlation between rate of H. pylori infectionand 
incidence of gastric cancer. This Asian or African paradox suggests that H. 
pylori by itself cannot cause gastric cancer and various other factors are needed 
for causation.
7
Thus, various etiological factors including smoking, alcohol, 
nitrates, and H. pylori have been proposed as causative factors for gastric 
cancer. 
From these epidemiological studies, it implicates that gastric cancer  is 
not a single disease or caused by a single factor, but a combination of genetic, 
sociocultural, and environmental factors in a given region and that  dictates its 
presentation. 
PATHOLOGY 
Any malignant tumor that arise in stomach that involve regionfrom the 
gastro-esophageal junction to the pylorus is referred as Gastric cancer(GC). 
Tumor of epithelial origin,adenocarcinoma constitutes about 95 per cent of 
stomach tumors. Other epithelial tumors like adenosquamous, squamous and 
undifferentiated carcinomas are rare.
8
Gastric cancer was broadly classified in 
mid 1960s as intestinal or diffuse type as proposed by Lauren et al. based on 
histological findings.Each type has distinct clinical and epidemiological pattern 
of presentation.The well-differentiated intestinal-type have neoplastic cells that 
is cohesive and forms tubular structures resembling gland. This type of tumor 
usually ulcerates. On the other end,poorly differentiated diffuse-type is 
characterized by thickened stomach wall due to infiltrationof tumor diffusely 
without discrete mass and thisresembles like a leather bottle in barium study. 
Epidemiologically, intestinal-type, is more common in men of old age with high 
prevalence in African-American with betterprognosis. And, this type of tumor 
generally arises from precancerous lesions like atrophic gastritis and intestinal 
metaplasia and influenced by environmental factors like H. pyloriinfection, high 
salt intake,obesity.The diffuse-type is the more prevalent in endemic areas and  
present in younger age with genetic susceptibility. Some tumor cells have both 
intestinal and diffuse type of cells and are termed as mixed gastric carcinoma. 
 
 
Histopathologic types of 
gastric cancer. 
A, The intestinal type of gastric 
adenocarcinoma is 
characterized by the formation 
of tubular structuresmimicking 
intestinal glands.  
B, The diffuse type of gastric 
adenocarcinoma contains singly 
invasive tumor cells that 
 
 
Clinicopathologic features of intestinal and diffuse types of  
gastric adenocarcinoma. 
 Intestinal Type Diffuse Type 
Gender Males  >females(2:1) Males = females 
Age  Older age(> 50yrs) Younger age(< 50yrs) 
Areas High risk(Japan,china) Uniform across the 
world. 
Incidence Decreasing Increasing 
Inheritance Hereditary nonpolyposis colorectal 
cancer,FAP 
Hereditary Diffuse 
gastric Cancer 
Location  Antrum(Distal) Corpus/body,anywhere 
Growth 
Pattern 
Usually exophytic Flat,ulcerated,linitis 
plastic 
Histology Gland formation,extracellularmucin. Loss of 
A B 
cohesion,signet ring 
cells,no. glands. 
Precursors Correa pathway:Chronic 
H.pylorigastritis,atrophy,metaplasia 
,dysplasia. 
Carneiro pathway: 
hereditary diffuse 
gastric cancer. 
 
In 2010, WHO revised the classification according to the morphological 
patterns commonly exhibited by the tumor into five major types 1.Papillary 
2.tubular 3.mucinous (mucinous poolexceeding 50% percent of tumor) 4.poorly 
cohesive (signet ring cell typeand other variants) and 5.mixed adenocarcinoma.
9
 
  
Lauren and WHO classification of gastric cancer 
Lauren  WHO classification  2010 
Intestinal Type Papillary adenocarcinoma 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Diffuse Type Poorly cohesive carcinoma(Signet ring 
and its variants) 
Mixed(equal intestinal and diffuse) Mixed type(glandular and poorly 
cohesive) 
Indeterminate Undifferentiated carcinoma 
 Adenosquamous carcinoma 
Carcinoma with lymphoid stroma 
Hepatoid adenocarcinoma 
Squamous cell carcinoma. 
 
NCCN 2013 guidelines for management of gastric cancer uses American 
joint committee on cancer staging  system which grade gastric cancer in 4 
grades as follows grade G1 = well differentiated ,G2 = Moderately 
differentiated G3 = Poorly differentiated   and G4 = Undifferentiated based on 
histological pattern. 
Invasive gastric carcinoma develops from precancerous lesions through 
stepwise evolution that include atrophic gastritis → intestinal metaplasia →  
dysplasia → carcinoma.Intestinal type gastric cancer follows this metaplasia/ 
dysplasia/carcinoma sequence that develops as a result of series of 
alterations/mutation in gene. 
 
 
  
Fig.A Correa cascade of gastric carcinogenesis. 
 
  
Diffuse type of gastric cancer are mostly sporadic however ,familial 
clustering is present in 10% and 1% to 3% of gastric cancers arise as a 
hereditary syndrome.These tumors follow different pathway of cancer genesis 
described as carneiro model as follows 
 
Fig .B The Carneiro modelof hereditarydiffuse gastric cancer. 
 
Etiology 
Gastric cancer is a disease of complex etiology involving multiple risk 
factors and multiple genetic and epigenetic alterations. 
 
 
Even though many factors are postulated as etiology for development of 
gastric cancer, H.pyloriinfection have been attributed to about 80% of cases. 
Other factors such as dietary habits, lifestyle habits, genetic factors and 
socioeconomic status also have contribution to cancer formation. 
Helicobacter pylori. 
 
H. pylori isa spiral,microaerophilic,gram negative bacteria that resides in 
gastric mucosa of patients and cause gastritis leading to chronic atrophic 
gastritis. There is two times increased risk of gastric cancer development in 
patients with H.pylori infection as evidenced by various meta-analysis.
10
 
The mechanisms by which H. pyloricontributes to carcinogenesis has 
been extensively studied, andit has been found that virulent strains in a 
permissive microenvironment induced cancer in a genetically susceptible host. 
The sequential progression of changesfrom normal gastric epithelium to 
carcinoma as described above had been suggested to be triggered by H.pylori.
11-
13
The products like urease,phospholipase,ammonia secreted  by the bacteria 
cause mucosa damage and loss of  barrier function through activation of urease-
mediated myosin II.
14
Oxidative stress generated by this products acts as 
virulence factor and leads to production of oxygen free radicals and nitrogen 
species. This redox potential cause oxidative DNA damage. The damage due to 
oxidative stress occurs only in susceptible host with H.pylori infection.
15 
H. pylori does not cause direct mutation in host cell but favors the 
production of such substances through cytokines release. Another mechanism 
speculated for mutagenicity   isimpairment of mismatch repair 
pathway.
11,16
These mutations in nucleus and mitochondria leads to aberrant 
DNA methylation. This epigenetic alteration (aberrant DNA methylation) is 
important inducer of carcinogenesis in gastric cancer. 
The cag pathogenicity island (cagPAI)containing strains of H.pylorihas 
been found to be most virulent by various epidemiological studies.Other 
virulence factors demonstrated are SabA,BabA,VacA.The CagA 
proteinbecomesphosphorylatedafter binding to gastric mucosa through tyrosine 
phosphorylation by SRC family kinases. This Phosphorylated CagAtransmits 
positive signals for cell growth and motility by selectively binding and 
activating SHP2, a phosphatase.This further activates translocation of B-catenin 
and p120 to nucleus,altering transcription of genes leading to increased 
proliferation, angiogenesis and inhibition of apoptosis.[Figure.C ]. 
 
 
 
 
 
 
 
 
Dietary factors 
Excessive salt intake plays a strong role in gastric carcinogenesis as 
evidenced by many epidemiological and experimental studies. Increased 
consumption of dietary salt is  reported to  increase the  risk of cancer 
development evidenced by themeta-analysis of prospective studies done by  D 
Eliaet al.
18
Salt cause direct damage of gastric mucosa and results in gastritis 
Fig :CH.pylori virulence factors SabA,CagA,BabA and VacAinflunces outcome of 
infection. 
CagA and VacAs1m1 types increases the disease severity.cagAactivate translocation 
of B-catenin and p120 to nucleus,altering transcription of genes that promote 
disease progression  
Host genetic diversity also contributes to cancer,including polymorphisms 
within IL-1b,IL- 10 and IL - 32 
 
 
 
which increases risk. Anotherhypothesis  is that salt induceshypergastrinemia 
and this leads  parietal cell proliferation and tumor progression. 
    Dietary nitrates are also found to contribute to carcinogenesis.  Mutagenic 
compounds are produced guanidine, L-arginine-containing polypeptides 
thatfound in natural food undergo nitrosation and  if nitrate in food come in 
contact to gastric acid.Other dietary factor found to have association is the one 
found in smoked food -benzo[a]pyrene.
9
 
 
 
 
 
 
Lifestyle 
Sjödahlet al[20]  in his  population-based prospective cohort study 
observed  that intake of alcohol and tobacco directly increase the risk of 
Host iron(Fe) levels and salt (NaCl)concentrations also affect virulence of H.Pylori. 
High salt increases cagA production and low iron levels increase assembly of T4SS 
pili,cagA translocation and IL-8 secretion. 
development of gastric cancer.The mechanism by which smoking perpetuate the 
carcinogenesis is by decreasing prostaglandins that maintain integrity of  gastric 
mucosa.  
H.pylori incidence is higher in smokers than non-smokers. A European 
study
21
 reported that there is significant association between smoking duration 
and intensity with  gastric cancer development.The mechanism for injury 
induced by smoking was decreased production of prostaglandins that maintains 
mucosal integrity. A recent study had shown that in patients who had curative 
surgical resection for cancer, continuous smoking habit was found to be a 
significant independent risk factor for death from gastric cancer 
22.
 
 
GENETIC ANDEPIGENETIC ALTERATIONS. 
 
The study on gastric carcinogenesis is an evolving field in research. 
Mechanism of cancer development is a complex biology and involves multiple 
step whereby normal cell is transformed  to  tumor cell with invasiveness. 
Alterations in  various genes that control cell growth like  tumor suppressor 
genes, DNA repair genes, cell cycle regulators, and signaling molecules has 
been demonstrated in gastric cancer. 
Recent studies had shown that fordevelopment of gastric canceran average of 
4.18 genomic alterations are necessary.
[23]
 Genomic alterations and subsequent 
Genomic instability   may be due to either chromosomal instability(CIN)or 
microsatellite instability (MSI). 
Chromosomal Instability(CIN) 
Chromosomal aneuploidyis the common chromosomal abnormality that most 
gastric cancer exhibits. Sasaki et al reported that aneuploidy was present in both 
differentiated tumors&undifferentiated tumors in about 72% and 43% 
respectively. 
Comparative genomic hybridization(CGH) analyses have revealed 
several changes in copy number of DNA. Decreased copy number was 
exhibited in chromosomal arms 4q, 5q, 17p&18p and increased number of copy 
in chromosomes 8q, 17q& 20q.Analyses also  shown that  20q gains and 18q 
losses were more  frequently seen in tumor that metastases to lymph node. 
 Analysis by comprehensive loss of heterozygesis(LOH) have revealed 
that   3p,4p,8q,17p& 18q were lost in majority of tumor cells. Younger patients 
have shown to have numerous variations in DNA number of copy and gains 
inthese chromosomal regions 6p21, 9p34, 11q23, 17p13, 19p13 & 22q13.
25
 
 Microsatellite instability(MSI) 
Gastric cancers with familial clusteringshows microsatellite 
instability(MSI),that results from errors in DNA replicationin about 15 – 20 
percent.Intestinal-type gastric cancer of advanced stage with invasiveness was 
associated with epigenetic inactivation of  the gene hMLH1
26
whereas sporadic 
cancer with less invasiveness was associated with mutations in transforming 
growth factor-β (TGF-β) RII,BAX  genes and  insulin-like growth factor-
II(IGF-II) R. 
 
Acquired somatic genetic/Molecular alterations. 
Oncogenes 
Fig:DMultiple genetic and epigenetic alterations during gastric carcinogenesis 
Oncogenes alterations due to mutation like activation /overexpression has 
been has been documented in gastric cancer.Intestinal- type cancer and its 
precursor lesions were demonstrated to have mutated K-ras oncogene in codon-
12. Anotherdemonstrated alteration is overexpression of a cell surface receptor 
– 
c-erbB2/HER2in intestinal-type gastric cancer.
28
In diffuse-type gastric cancers, 
aberrations in the FGFR2/ErbB3/PI3 kinase pathway andamplification of c-met 
have been frequently documented.
28
 
 
 
 
Tumor Suppressor genes. 
TFF -1 loss 
More than 50% of gastric cancers has been demonstrated to have ‘loss of 
Trefoil peptide TFF1(pS2)’.Gastrokine(GKN) 2,a stomach specific tumor 
suppressor protein was structurally and physically similar to TFF1 and loss of 
GKN1 and GKN2 expression was found in gastric adenocarcinoma. 
 
p53 gene 
Altered p53 gene is consistently seen in gastric adenocarcinoma with loss 
of allele in 60% of cases and about 30 to 50% of cases shown mutation.
30
 
 
Cell cycle regulators, growth factors and cytokines 
Gastric tumor cell produce many growth factors and cytokines which 
controls the cell growth, differentiation and activation  throughTGF-B pathway.  
Dysplastic cells shown increase in the expression of Transformation growth  
factor (TGF) beta -1/2, TGF-beta R1, MYC &TP53 along with overexpression 
of SMAD4, CDKN1A, SMAD2/3 &CDKN1B  while overexpression  ofTGF –
beta R2, SMAD7, RELA&CDC25A  had been observed in both dysplasiaand 
carcinoma.
31
Many meta  -analysis and reviews reported that risk of gastric 
cancer increases with presence of gene polymorphisms atpositions -511, 31 and 
+3954 in Interleukin (IL)-1beta  cluster.
32
 
 
Others 
E-cadherin alteration (reduced expression), Methylation silencing 
alterations(CpGhyper methylation) and apoptosis signaling alterations (mutation 
of BAX gene) were demonstrated inabout 26%,41% and 33% of gastric 
adenocarcinoma respectively.
33,34
 
 
Biomarkers : For Diagnostic,Prognostic,Treatment Guidance. 
The high mortality rate in GC is due to delayed detection and surgical 
resection at advanced stages of disease.Currently,detection of early tumors is 
limited as there are no reliable markers.Major research is being made to develop 
the molecular signature based methods complementing histo pathological 
diagnosis that can prognosticate the patient. 
Various biomarkers like CA 10-9,CEA,phospholipase A2,TGf-B1,VEGF 
and others had been tried but all shown to have poor sensitivity and specificity. 
Serum markers like tissue inhibitor of metalloproteinase(TIMP-
1),interleukin-10,hepatocyte growth factor, interleukin-2 soluble receptor  and  
E-cadherin soluble fragment have been reported in more invasiveness tumors 
with  poor survival
.35,36
 
Serum Proteomic evaluation  of  GC patients revealed  that a panel of  5 
proteinmarker  consisting of Ago2 miRNA,MiR-187,miR-371-5p,miR-378 and 
miR-486 shown to have sensitivity and specificity of 83% and 95% 
respectively.
37
.But,this need validation since this study had small sample 
sizeand were mostly retrospective and case control study. 
 
Chemosensitization Markers 
Response to specific treatment agents can be predicted from identification 
of molecular markers in tumor cells. Markers like overexpression of p53,BAX 
and Bci-2 staining was observed in small group of patientsand that showed poor 
response and chemoresistant to currently available chemotherapy 
agents.(38,39). 
With good molecular analysis and better understanding of 
cancerogenesis,molecular targeted therapies are being developed.One such 
molecular target identified was HER2/neu receptor, against which therapeutic 
agent showed improved survival.   
The protein,HER2/neu (ERbB-2) is a 185-kDa trans-membrane tyrosine kinase 
receptor belonging to the family of epidermalgrowth factor receptors 
(EGFRs).There are four members in the family:HER1 (EGFR), HER2, HER3 
(ErbB-3) andHER4(ErbB-4).All have samemolecular structure with an 
extracellular ligand-binding domain, an intracellular domain with tyrosine 
kinase activity (excepting the HER3)and a short trans-membrane domain.Signal 
transduction for cell proliferation and processing is initiated if ligands bind to 
extracellular domain through homodimerization as well as heterodimerization. 
HER2 does not bind to any known ligand, but it is the preferred 
heterodimerization partner forother members of the HER family.  
A gene located on long arm of chromosome 17 encodes HER2. 
Topoisomerase IIa genes are located adjacent to this gene and it is  a oncogene.  
HER2 enact as an oncogene in gastric and other cancer by highlevel of 
amplification and thereby stimulates protein overexpression in the cell 
membrane and provide good microenvironment for growth of malignant cell. 
Initially,HER2 overexpression/amplification was studied well in breast 
cancer and detected in  invasive breast cancers in about 10%–34%.Presence of 
this overexpression was  correlated with the clinical outcome, and found to be 
poor prognostic marker. Further studies,reported that this marker constitutea 
predictive factor of poor response to chemotherapy and endocrine therapy. 
Later, HER2overexpression and/or amplificationhave also been observedin 
many cancers like colon, bladder, ovarian, endometrial, lung, uterine 
cervix,head and neck, esophageal and gastric carcinomas. 
A monoclonal antibody, Trastuzumab (Herceptin) was then developed against 
HER2 whichby directly binding the extracellular domain of the receptor 
specifically targets HER2 protein. Clinical studied demonstrated that this 
monoclonal antibody increases the survival rates in both primary and metastatic 
HER2-positive breast cancer patients. This advantage of trastuzumab made the 
researcher to study the efficacy of it in otherHER2-positive cancers, including  
gastric adenocarcinomas. 
For the past 2 decade, large number of studies had been published on 
HER2 positivity in gastric cancer and many studied the correlation between 
HER2-postivity and survival with/without association with important 
clinicopathological characteristics. 
In 1986, Sakai K et al
40
 first described the amplification of  HER2 protein 
in gastric cancer using immunohistochemistry (IHC).Then, in 1990’s case 
seriesstudied the incidence of positivity of  HER2 in tumors using polyclonal 
antibodies directed against various domains of HER2 protein and reported the 
incidence rate being 9%–38%. From 2002 onwards, IHC using monoclonal 
antibody with/without gene amplification by FISH is being done.The 
commercially available kit is called HercepTest. 
 
               On systemic review of articles related to HER2,so far 48 articles 
comprising 17,338 patients were published. Out of these, 38 article comprising 
11,860 patients studied the correlation between the HER2 status and relevant 
clinico-pathological variables such as vascular& tumorinvasion,lymph node 
involvement, metastases status, stage of diseaseand  survival.  The weighted 
mean HER2-positive status from the articles was 17.9% (95% CI; 14.8 to 20.9) 
ranging from 4.4% to 53.4%. Except two articles (also included OGj tumor), all 
articles studied cancer localized to stomach.  
 
Study Country 
 
N HER2 
positivity 
Prognosis 
Information 
Yonemura Y et al(1991)
41
 
 
Japan 
 
260 
 
11.9 
 
++ 
MizutaniT et al(1993)
42
   
 
Japan 226 14.0 ++ 
Chariyalertsak et al(1994)
43
  
 
Thailand 309 11.7 + 
H Allgayer et al. (2000)
44
 
[4 
 
 
Germany 189 53.4 ++ 
JPintoet al(2002)
45
  
 
Portugal 157 15.3 ++ 
KE Lee et al. (2003)
46
   
 
Korea 841 16.9 - 
GZ Yu et al. (2009)
47
  
 
China 1143 
 
28.0 + 
H Grabsch et al. (2010)
48
 
 
UK 506 44 - 
Kim et al. (2011)
49
 
 
Korea 2009 13.8 ++ 
Y Wang et al. (2011)
50
  
 
China 436 20.6 ++ 
Sekaran et al.(2012)
51
 India 52 44.2 NA 
 
  
Correlation of HER2 expression with pathologic variables 
 
Several studies in 1990s reported high correlation between HER2 
expression and intestinal type of gastric cancer. More recent studies also 
confirms this as follows 
Study 
N 
 Histologic type 
 
Localization 
Intestinal 
 
(%) 
Diffuse 
(%) 
Mixed 
(%) 
 P 
value 
GEJ 
(%) 
Gastric 
(%) 
P 
value 
Tanner et al[52]   
-  231  
21.5 2 5 0.005 24 12 - 
Gravalos et 
al[53]. 166  
16 7 14 0.27 25 9.5 0.001 
Lordick et al[54]. 
1527  
34 6 20 - 32 18 - 
 
Detailed review on correlation of HER2 overexpressionwith  clinical and 
pathological parameters were studied by various author over the past two 
decades. Most of the authors correlated the factors like 
age,genderdifference,location of tumor, histologicalpattern, clinicalstaging, 
lymph node metastasis, serosal involvement with and without HER2 positive 
gastric cancer.Results of these studies was summarized and given below(table-
).There was difference in results in these studies but generally more study 
reported that HER2 positivity correlates with intestinal type gastric cancer with 
advanced stage like nodal metastasis.Thus,it seems to be a prognosticate marker   
for advanced malignancy 
List of Studies on clinicopathological correlation& their results. 
Parameters  Significant 
 (positive 
correlation) 
Non-significant 
   (no correlation) 
Age Young  Grabsch et al
48
, Marx 
et al
55
, Barros-Silva 
et al
56
 
Older Grabsch et al
48
,Marx 
et al
55
, Barros-Silva 
et al
56
 
 
Gender Male Lee et al
65
 Wang et al
67
,Marx et 
al
55
, Barros-Silva 
et al.
56
 
Female   
Lauren 
classification 
Intestinal Grabsch et al
48
,Marx 
et al
55
, Barros-Silva 
et al
56
. 
Wang et al
67
, Song et 
al
63
,Pinto-de-Sousa 
et al
66
. 
Diffuse/Mixed   
WHO 
classification 
Papillary/tubular Grabsch et al
48
,Im et 
al
62
,Lee et al
65
. 
Wang et al
67
,Song et 
al
63
,Pinto-de-Sousa 
et al
66
. 
Tumor 
grade 
Well 
differentiated 
Grabsch et al
48
, Lee 
et al
65
. 
Wang et al
67
,Marx et 
al
55
, Song et al
63
. 
Mod/poorly 
differentiated 
Yu et al
59
, Wang et 
al
67
. 
 
Tumor 
location 
Proximal Yu et al
59
, Pinto-de-
Sousa et al
66
. 
Wang et al
67
,Marx et 
al
55
, 
Potrc et al
61
,Garcia et 
al
64
Ghaderi et 
al
68
,Allgayer et al
69
 
 Distal   
 
Tumor 
 
Early 
  
Grabsch et al
48
,Marx 
depth (T) et al
55
,Yu et al
59
. 
 Advanced Wang et al
67
,Im et 
al
62
. 
 
Lymph node 
metastases 
(N) 
N0  Grabsch et al
48
,Marx 
et al
55
, Barros-Silva 
et al.
56
, Yu et al
59
. 
 N1/N2/N3 Wang et al
67
,Bazas et 
al
71
,Potrc et al
61
, 
Im et al
62
. 
 
Presence of 
metastases 
(M) 
Liver Ougolkov et al
70
  
Peritoneal No study  
TNM 
staging 
I/II  Marx et al
55
, Barros-
Silva et al
56
. 
 III/IV Wang et al
67
,Im et 
al
62
, 
Ghaderiet 
al
68
,Allgayer et al
69
. 
 
 
 
Correlation between  HER2 overexpression and survival 
 
There were 39 studies which reported resection rates in both HER2 
positive and HER2 negative gastric cancers.30 studies reported R0 resection.35 
studies reported correlation of  HER2 overexpression with overall survival.Out 
of 35,20 studies (57%) reported that there was no difference in overall survival 
in patients with and without  HER2 amplification.13 studies (37%)  
demonstrated poorer overall survival that was statistically significant.Two 
studies reported longer survival but there was selection bias in those studies. 
From these studies, the median overall survival or 5-year survival rate were 
21months and 33monthsrespectively in patients with and without HER2 
overexpression, respectively 
 Number of studied that reported disease-free survival (DFS) was six. 3 studies 
reported significantly poorer DFS in patients with HER2 overexpression while 
the remaining otherthree studies reported no difference in DFS of patients with 
and without HER2 overexpression.Data were available on 3and 5- year  DFS 
from four studies. The median 3-year DFS rate was 58% (range, 50–88%) and 
86% (range, 62–97%) while median 5-year survival rate was 42% (range, 0– 
94%) and 52% (range, 5–87%) in patients with and without HER2 
overexpressionrespectively. 
 
Study 
Author 
3-Year disease 
free survival (%) 
 
Median 
survival 
(Months) 
5-Year survival 
(%) 
 
HER2 
+ve 
HER2 
-ve 
p  
 
Value 
 
HER2 
+ve 
HER2 
-ve 
HER2 
+ve 
HER2 
-ve 
P 
Value 
Grabsch
48
 NR NR NR 30 48 42 46 0.903 
Barros
56
 NR NR NR 30 60 45 50 0.222 
Im
62
 58 97 0.003 30 NR 35 77 0.004 
Vizoso
72
 shorter DFS 0.01  HER2 +ve shorter OS 0.04 
Allgayer
69
 50 80 0.002 19 35 NR NR 0.016 
Median  58 86  21 33 42 52  
 
Therapeutic Implication 
 
Chemotherapy - Anti-HER2 therapy: trastuzumab 
ToGA trial
73
 
Trastuzumab in combination with chemotherapy versus chemotherapy 
alone for treatment of HER2-positive advanced gastric or gastro-oesophageal 
junction cancer (ToGA): a phase 3, open-label, randomized controlled trial had 
showed survival benefit. 
The trial was conducted in 24 countries over 122 centersfor patients with 
gastro-oesophageal junction and gastric cancer if their tumors showed 
overexpression of HER2 protein by immunohistochemistry(IHC) or gene 
amplification by fluorescence in-situ hybridization(FISH). The primary 
endpoint was overall survival in all randomizedpatients who received study 
medication at least once.584 patients (n=294,n=290) were randomly divided 
into treatment( trastuzumab plus chemotherapy) and chemotherapy alone group 
and followed for 18.6 months. 
The median overall survival was 13·8 months (95% CI 12–16) in treatment 
group vs 11.1 month in chemotherapy alone group( hazard ratio 0∙74; 95% CI 
0∙60–0∙91; p=0∙0046) with no significant adverse side effect due to drug. Based 
this study,European and American  cancer union has recommended  
trastuzumab as a new standard treatment  option for patients with HER2-
positive advanced gastric or gastro-oesophageal junction cancer when combined 
with a chemotherapy regimen consisting of capecitabine plus cisplatin or 
fluorouracil plus cisplatin. 
Thus,HER2 positivity seems to be reliable prognosticate marker for 
gastric cancer and  monoclonal antibody therapy against this receptor protein  
along with chemotherapy  is a potential therapeutic option  for gastric cancer of  
advanced stage disease with  definite survival benefit. 
The prevalence of this subtype of gastric cancer in India is not yet studied 
except in a study.So,we intended to study the frequency ofHER2 overexpression 
in our population and to find the correlation with clinical and pathological 
variables.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
To study the incidence and clinico pathological correlation of HER2 positivity 
in  gastric malignancy 
Primary outcome 
1. To find the incidence of gastric, oesophago gastric  junction cancer  
with HER2overexpression. 
Secondary outcome 
1.Correlation  of  HER2 overexpression with clinical staging. 
2.Correlation  of  HER2 overexpression with pathological variables. 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
This is a hospital based prospective cohort study, done at Department Of 
Digestive Health and Sciences, Government Peripheral hospital, Anna nagar, 
Chennai from June 2013 to February 2014.  
          All consecutive patients  of  gastric adenocarcinoma diagnosed during  
the study  period   were enrolled in the study. The diagnosis of gastric 
adenocarcinoma was made in endoscopic gastric biopsy specimen by the 
pathologist.Written informed consent was obtained from all participating 
subjects in regional language and privacy of  illness wasensured. 
All enrolled patients were assigned a case number and  details like age, 
residential address  along with contact number were noted. Clinical presentation 
symptoms with duration  and  relevant  details  of  risk factors for  gastric 
cancer like smoking, alcohol intake ,previous  peptic ulcer disease, dietary 
history, socioeconomic status and previous gastric surgery details were noted. 
All positive signs on clinical examination  and relevant blood investigations 
were noted. 
Tumors were tested for HER2 status using immunohistochemistry (IHC) on 
formalin-fixed paraffin-embedded sectionsof  biopsy specimen.Antibody 
against HER2 ,Hercep test kit (polyclonal rabbit anti tumor cer-B2 onco-
protein-DAKO) was used  and was done in medall diagnostic lab,Chennai.   
Scoring for HER2 overexpression was done by two independent experienced 
pathologist based on validated Hofmann et al. scoring  for gastric 
adenocarcinoma as given below. 
Expression of HER2 was graded  from score 0 to 3 and score of  3+ was 
considered as positive for HER2 overexpression.  
 .  
 
 
 Overexpression of HER2 in gastric adenocarcinoma was evaluated and 
correlated with various clinical and  pathological parameters like 
age,gender,and histological parameters like grading of differentiation,type of 
adenocarcinoma(intestinal vs Diffuse).To stage the disease, CT scan of 
abdomen with lower thorax  and/or ascitic fluid analysis for malignant cells 
IHC score 1+ IHC score 2+ IHC score 3+ 
Consensus  panel  recommendation for HER2 evaluation og gastric cancer from Hoffman validation 
study[74] 
POSITIVE 
were done. Clinical staging was done as per TNM classification as follows  
where T = Tumor depth, N= Nodal involvement and M= metastasis 
 
 
 N0 N1 N2 N3 M1(Any N) 
Tis Stage 0 - - - - 
T1 Stage IA IB II IV IV 
T2 IB II IIIA IV IV 
T3 II IIIA IIIB IV IV 
T4 IIIA IV IV IV IV 
 
T1=  tumor confined to the mucosa or submucosa,  
T2 =  tumor involves of the muscularispropria, 
T3 = tumor  invades through the serosa, and 
 T4 = tumor invasion  into adjacent organs or structures. 
N0  =  no lymph node involvement, 
N1 =  involvement of 1 to 6 regional lymph nodes, 
N2 =  involvement of 7 to 15 regional lymph nodes,  
                                                                            N3= involvement of more than 15 regional lymph nodes 
                                                                             M1=Presence of distant metastasis 
 
 
 
 
 
 
 
Follow-up 
             Study population wasfollowed up during the study period. Treatment 
received by the patient like curative or palliative surgery with or without 
chemotherapy or palliative supportive care was recorded. Patient was asked to 
follow up every 3 months. If not followed up after 4 months, patientwas 
contacted through telephone and enquired about treatment and survival details. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
A total of 70 patients with histopathological diagnosis of gastric 
adenocarcinoma were enrolled during the study period. 9 patients were not 
willing for HER2 immunohistochemistry testing.61 patients in whom test was 
done were included for study analyses. 
Statistical analysis was done using SPSS software (Version 
17).Univariate and Multivariate analysis was done. Chi square value and fischer 
exact probability  were used to compare variables of  two study  arms. P value 
<0.05 is considered statistically significant 
AGE DISTRIBUTION 
 Majority of patients were in age group >60 years and  middle age. 5 
patients were < 40yrs of age with youngest patient  being a 19 years old boy. 
Age Number of subjects Percentage 
<40 yrs 5 8.3 
40-60 yrs 24 39.3 
>60 yrs 32 52.4 
Table.1 : Age group distribution of study population. 
 
       Fig.1: Age group distribution 
GENDER DISTRIBUTION 
Male predominates with 53 out of total of 61 patients with sex 
ratio of 6.7 : 1. 
Gender Number of subjects Percentage 
Male 53 87 
Female 8 13 
Table.2 : Gender distribution of study population 
5 
24 
32 
0
5
10
15
20
25
30
35
< 40yrs 40-60 yrs >60 yrs
< 40yrs
40-60 yrs
>60 yrs
 Fig.2 : Gender distribution. 
CLINICAL PRESENTATION 
Constitutional symptom like loss of  weight and appetite was the 
commonest presenting complaint accounting for 80-90% followed by  
abdominal pain in 77% and vomiting in 64%.[Table.3 & Fig.3]  
Presenting Complaints Number of subjects Percentage 
Abdominal Pain 47 77 
Vomiting 39 64 
Early satiation 26 43 
Loss of weight 56 92 
Loss of appetite 49 80 
Table.3:Frequency of presenting complaints. 
 
0 
53 
8 
Male
Female
              Fig.3: Presenting complaints and its frequency. 
RISK FACTORS 
In our study major  risk factor identified were smoking and chronic 
alcohol intake with association of about 72% and 66% respectively. Previous 
history of peptic ulcer was present in about one fifth of subjects. Past history of 
gastric surgery was present in only 4 out of 61 patients. 
 
 
Risk factors Number of subjects Percentage 
Smoking 44 72 
77% 
64% 
43% 
92% 
80% 
0% 20% 40% 60% 80% 100%
Abdominal Pain
Vomiting
Early satiation
Loss of weight
Loss of appetite
Abdominal Pain
Vomiting
Early satiation
Loss of weight
Loss of appetite
Alcohol 40 66 
Previous Peptic ulcer disease 13 21.3 
Previous Gastric surgery 4 6.5 
Table.4: Risk factors present in study population. 
 
 
                 Fig.4: Depicts risk factors and its frequency. 
 
 
 
 
 
 
CLINICAL SIGNS 
 Clinical signs were less frequent compared to symptoms at time of 
presentation. Mass palpable per abdomen was elicit able in 13% and sign of 
72% 
66% 
21.30% 
6.50% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
Smoking Alcohol Previous
Peptic ulcer
disease
Previous
Gastric
surgery
Smoking
Alcohol
Previous Peptic ulcer disease
Previous Gastric surgery
distant metastases like hepatomegaly due to metastasis and ascites was present 
in 21% and 15% respectively.  
 
Clinical Signs Number of subjects Percentage 
Mass per abdomen 8 13.1 
Hepatomegaly 13 21.3 
Ascites 9 14.8 
Table.5: Major clinical sign and its frequency. 
 
Fig.5: Frequency of clinical signs present in study population. 
LOCATION OF TUMOR 
Only one patient presented with growth at gastric cardia and rest 60 
patients presented with tumor in distal stomach. Antrum was the commonest  
13.10% 
21.30% 
14.80% 
61% 
Mass per abdomen
Hepatomegaly
Ascites
No finding
location of tumor(about 40 percent), followed by body and involvement of both 
body and antrum in 26 and 23 percent respectively.  
Diffuse infiltrative type of gastric cancer (linitusplastica) was noted in 6 
patients accounting for about 10 percent. 
Site Number of 
subjects 
Percentage 
Proximal 
- Osophagogastric  Junction 
- Gastric Cardia 
1 
1 
0 
1.6 
Distal 
-Body 
-Antrum 
-Both Body and antrum 
- Diffuse Linitusplastica 
60 
16 
24 
14 
6 
98.4 
26.3 
39.3 
23.0 
9.8 
Table.6: Site of location of tumor and its frequency.  
 Fig.6: Percentage distribution of gastric cancer based on location. 
GRADING OF TUMOR  
Histologically tumor cells were graded depending on degree of 
differentiation as well differentiated to poorly/ undifferentiated cells. In our 
study, 46% of patients had moderately differentiated tumor cells and 21% had 
poorly differentiated tumor cells. One patient had signet ring type 
adenocarcinoma and two patients had scirrhous type adenocarcinoma. 
 
 
HPE Number of subjects Percentage 
Well Differentiated 13 21.2 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
Body Antrum Both Diffuse
Linitis
plastica
26.30% 
39.30% 
23% 
9.80% 
Body
Antrum
Both
Diffuse Linitis plastica
Moderately Differentiated 28 46.0 
Poorly Differentiated 17 27.8 
Diffuse type-poor cohesion 3 5.0 
Table.7: Different grades of differentiation on histology and its prevalence. 
 
Fig.7: Percentage distribution of grades of differentiation. 
 
CLINICAL STAGING 
Based on oral and intravenous Contrast enhanced CT abdomen, clinical 
staging was made. None was presented at early stage of disease. Majority 
presented at advanced stage of  disease with 46% in stage III and 28% in stage 
IV. 
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27.8% 
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Differentiated
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Differentiated
Diffuse type-poor
cohesion
Clinical stage Number of subjects Percentage 
I 0 0 
II 16 26.2 
III 28 45.9 
IV 17 27.9 
Fig.8: Frequency of clinical stages of gastric cancer in study population.  
 
             Fig.8: Percentage distribution of clinical stages 
 
 
HER2 OVEREXPRESSION STATUS. 
0
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Out of 61 cases, HER2 overexpression was positive with 3+ staining in 
21 patients, constituting 34.4% of  study population. One example shown 
below. 
 
 
 
HER2 Overexpression Number of patients Percentage 
Case no 43 : HPE  showing 
moderately differentiated 
adenocarcinoma 
Case no 43 : Immunohistochemistry of 
same patient showing  3+ staining 
pattern 
Positive(3+) 21 34.4 
Negative(less than 3+) 40 65.6 
Fig.9: Frequency of HER2 overexpression in study population. 
 
 
Fig.9: Percentage of HER2 positivity in study population. 
 
 
CORRELATION OF HER2 OVER EXPRESSION WITH 
VARIOUS CLINICAL AND PATHOLOGICAL VARIABLES. 
 
CORRELATION WITH AGE OF PRESENTATION AND GENDER 
34.4% 
65.6% 
0
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20
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50
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70
Positive(3+) Negative(less than 3+)
Positive(3+)
Negative(less than 3+)
           By univariate analysis HER2 overexpression was correlated with age and 
gender. Results (Table.10 & 11) revealed that there was no correlation between 
these variables and HER2 positivity.  
 
Table.10:Univariate analysis of HER2 overexpression  in various age groups. 
Age HER2 
overexpression 
Chi square 
value 
P value 
Yes No 
<40 4 1   
40-60 8 16 5.18 0.07 
>60 9 23   
 
Table.11:Univariate analysis of HER2 overexpression  in relation to gender. 
Gender HER2 
overexpression 
Odds ratio 
(95% CI) 
Fischer 
exact 
probability 
P value 
Yes No 
Male 17 36 0.47 (0.08-2.62) 0.99 0.27 
Female 4 4    
 
 
 
 
CORRELATION WITH LOCATION OF TUMOR. 
        There was no correlation between HER2 overexpression and location of 
tumor as depicted in below table (P value =0.656)  
Table.12: Correlation of HER2 overexpression with location of tumor.  
Site HER2 
overexpression 
Odds ratio 
(95% CI) 
Fischer 
exact 
probability 
P value 
Yes No 
Proximal 0 1 0.00 (0.00-
34.34) 
0.53 0.656 
Distal 21 39    
 
CORRELATION WITH CLINICAL STAGING. 
As stage of disease increases, the positivity of HER2 overexpression increases 
significantly. There was statistical significance (p value =  0.0003) correlation 
with clinical staging.   
Table.13: Frequency distribution showing HER2 overexpression in relation to 
gastric cancer staging 
Stage Number of 
cases (%) 
HER2 overexpression 
(n[%]) 
Chi square P - value 
Yes No 
I 0 - - - - 
II 16 (26.2) 1 (6.3) 15 (93.7)  
15.9 
 
0.0003 III 28 (45.9) 8 (28.6) 20 (71.4) 
IV 17 (27.9) 12 (70.6) 5 (29.4) 
 
 
CORRELATION WITH GRADING OF TUMOR. 
HER2 overexpression was more prevalent in intestinal type of cancer and 
in particular moderately to poorly differentiated type compared to well 
differentiatedtype.As degree of differentiation increase, HER2 positivity 
increases with statistical significance. 
Table.14: Correlation of HER2 overexpression with grades of differentiation of 
tumor cells. 
HPE HER2 overexpression Chi square P value 
Yes No value 
Well Diffentiated 1 12   
Moderately differentiated 8 20 10.40 0.015 
Poorly differentiated 10 7   
Undifferentiated/ 
Poorly cohesive type 
2 1   
 
FOLLOW UP RESULTS 
 During the one year study period, only seven patients had curative 
resection for cancer and none were in HER2 positive group. About 50% of 
HER2 positive patients were in advanced stage where palliative surgery and 
chemotherapy was not feasible due to poor performance status of patient. Those 
who received palliative chemotherapy were not able to complete the full course 
due to other complications and death. Only 2 patients in HER2 positive study 
arm were surviving till this study period, one patient was at 6
th
 cycle of 
chemotherapy and other patient was just started the first cycle of chemotherapy. 
In comparison other study arm, the survival rate was less in HER2 positive 
group (9.5% vs 15%)   
 
 
Treatment received 
HER2 overexpression 
Yes 
N=21 
NO 
N=40 
Underwent curative surgery and 
chemotherapy 
0 7 
Palliative surgery and received full 
course  palliative chemotherapy 
5 11 
Palliative surgery and received partial 
palliative  chemotherapy 
6 17 
Palliative Supportive care 
 
10 5 
Survival at end of study period (%) 2(9.5%) 6(15%) 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Gastric cancer is a potentially curable disease if diagnosed at early stage, 
where patient are mostly asymptomatic. And when patient with gastric cancer 
have clinical symptoms and present to clinician, majority are already in 
advanced stage of disease where curative treatment is not possible. Screening 
for detection of early cancer is proved to be not a cost effective strategy except 
in high prevalence area. Thus, in majority when diagnosis of gastric cancer is 
made, patient is left with the only treatment option of palliative surgery with 
chemotherapy. In addition, the response to chemotherapy is not uniform in all 
patients even at same stage of disease due to biological aberrations in tumor 
cells and this leads to poor survival results. Researches have shown that specific 
subgroup of patient with HER2 overexpression were found to have survival 
benefit if they were treated with antibody against HER2 receptor. With this 
data, National comprehensive cancer network (NCCN) recommends HER2 
testing as part of routine work up in gastric cancer patients. In India, the study 
on prevalence of subgroup of gastric cancer with HER2 overexpression is very 
scanty with only one study by Sekaran et al.  
Since our study is a hospital based study, the true incidence of gastric 
cancer in population cannot be ascertained but in our study we observed that 
there is increasing incidence of cancer in younger age group (<40 yrs) that 
constitutes about 8% of total case. Anderson et al also reported that there is 
unexplained increase in incidence in younger individuals.
74 
We had more male 
predominance of 6.7 : 1 as compared to GLOBOCAN 2008 data of 2 : 1 may be 
due to referral bias.  
Frequency of presenting symptoms like loss of weight and abdominal 
pain was about 90% and 70% in our study  compared to 60% and 50% 
respectively in  Waneboet al.
75This may be explained by  patient’s  habit of 
seeking medical advice at delayed phase. Smoking habit was present in 72% of 
our subjects as reported in various studies from European and Asia.
76-78 
We 
observed less prevalence of other risk factors like previous peptic ulcer disease 
and previous gastric surgery in our study cohort. 
36.1% of our study population present with metastasis at time of 
diagnosis. Liver was the most common site for metastasis followed by 
peritoneal in 21% and 15% respectively comparable to the previous studies.
79-81 
In our study intestinal type of gastric cancer was the predominant type as 
comparable to various population based studies.
45-49
 We had more patients 
(74%) in advanced stages (III & IV) of disease, may be due to late referral. 
 
 
 
HER2 Overexpression and correlation. 
In our study cohort of 61 patients, 21 patients had overexpression of 
HER2 accounting for 34.4%.This was comparable to various studies worldwide 
and from systemic review which reported the incidence in range of 9 – 38%.41-
49
Sekaran et al ,the other only  study from India reported the incidence being  
44.2%(23 out of 52 cases).No significant correlation was demonstrable between 
HER2 positivity and age and gender  distribution of cancer and this was 
comparable to the studies done by  Lee et al
46
 and Wang et al.
50
 
We had almost all ,except one patient withtumor located in distal stomach 
either antrum or body, hence could not be able to correlate the HER2 
overexpression with location of tumor. Previous studies had reported that HER2 
amplification was slightly more in proximal tumor compared to distal tumor.
52-
53
 but, this finding was not consistently seen in other studies.
54
 
       In our study, we had observed that there was definite correlation of HER2 
overexpression with clinical stage of disease. As stage of disease advances, the 
frequency of Her2 overexpression increases with statistical significance(p value 
=0.003). This was comparable to the studies done by Marx et al,
 55
 Barros-Silva 
et al,
 56
 and Park et al
82
   which all reported that there wasno significant 
correlation of HER2 overexpression with stage I/II disease. Study by Wang et 
al.
67
, Zhang et al.
58
Ghaderi et al.,
 68
Allgayer et al 
69
 reported that there is 
significant association between HER2 overexpression and stage III/IV disease. 
       Our study demonstrated that HER2 overexpression was more in intestinal 
type of gastric cancer than diffuse type with frequency of 43.5%, 47% and 9.5% 
in intestinal,mixed,diffuse type respectively. A Korean study
82
 also reported this 
correlation. ToGA trial
73
 also  had  similar results with frequency of HER2 
overexpression as follows- intestinal 34 %, diffuse 6 %, mixed 20 %.Sekaran et 
al reported equal distribution of HER2 positivity in both  intestinal and diffuse 
type of gastric cancer. 
          Follow up results of our study cohort cannot be extrapolated because 
mean duration offollow up was only 3.1 months. With the available data, 
majority of patients(n= 21) in HER2 positivity group(50%) had advanced stage 
of disease where palliative supportive care was the only treatment option left. 
One patient in this group had completed palliative chemotherapy and on follow 
up. One patient had just started first course of chemotherapy. All other patients 
in HER2 positivity arm, succumbed to death with incomplete course of 
chemotherapy  or medically unfit for chemotherapy. On HER2 negativity 
arm(n= 40), we have  6 patients on follow up, out of which one had curative 
resection and completed chemotherapy,4 patients were receiving chemotherapy 
and one patient was in supportive care.Thus,HER2 positivity was associated 
with poor survival outcome. 
 
 
 
Limitation of the Study. 
         Number of study population is less to extrapolate the results. Study 
warrants need for long duration follow up of study population. The associated 
comorbid medical conditions that can affect morbidity and mortality were not 
attested. Newer chemotherapeutic agents and good supportive care are not made 
available   to the patients due to non-availability and financial constraints.   
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
1. This study is first of its kind done in our part of country. 
2. Distal gastric cancer is more common than proximal gastric cancer. 
3. Majority of patients(74%) present at advanced stage of disease. 
4. In our study, HER2 positivity is observed in 34.4%. 
5. HER2 overexpression is positively correlated with advanced stage of 
gastric cancer with statistical significance. 
6. HER2 positive gastric cancer patients seem to have poor survival outcome. 
7. In future, HER2 testing may be a part of routine work up in gastric cancer 
patient to prognosticate the survival outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
